Italian Research	FY19 Results	Milan, March 18, 2020	
EL.EN.		OUTPERFORM	SECTOR: Industrials
Price (Eu):		16.00	Andrea Randone +39-02-77115.36 e-mail: andrea.randone@intermonte.i
Target Price (Eu):		26.00	Francois Robillard +39-02-77115.47 e-mail: francois.robillard@intermonte.it

Positive 4Q but difficult start to 2020 amid low visibility


- Strong performance across segments in 4Q. The Medical segment performed well in 4Q (+21.9% YoY vs our +19.5%) thanks to continued growth in Urology, Services, After-Sales and Aesthetics, with strong growth by the new star product, Onda Coolwave (€11mn in sales). Industrial segment growth was slightly higher than our forecast for 4Q (+7.7% vs our +1.3%) thanks to an outstanding performance in Europe and some recovery in China in December.
- 4Q19/FY19 top-line and EBIT in-line with guidance. Sales reached €117.9mn/€400.8mn and were up 14.9%/ 15.8% YoY, broadly in-line with our forecast (€396mn) and the indication from management for FY19 (~€400mn). Gross Profit was €44.9mn/€156.0mn, with a 38.1%/ 38.9% margin, down -2.1pp/ -0.8pp YoY and a touch below our forecasts (-2.5pp/-0.7pp respectively) due to a less favourable mix YoY across both the Industrial and Medical segments. EBIT was €13.7mn/€38.2mn, landing in the ballpark indicated by management (approx.. €40mn), with margins of 10.0%/9.5%, broadly in line with our forecasts.
- Strong cash flow and net income beat our estimates. Net Income for FY19 was €26mn, 16% above our €22.5mn estimate thanks to: i) the lower contribution from minorities (due to weak Chinese industrial performance); and ii) lower taxes than our estimate. Net cash was €61.4mn, beating our estimate due to: i) the timing mismatch in accounting for the Chinese minority acquisition (only €-2mn for Wuhan acquisition registered in 2019 vs €-22.5mn for both deals in our est.); and ii) strong FY19 operating cash flow of €37.7mn (vs our €25.9mn) thanks to lower cash absorption from WC compared to our estimate.
- Cautious messages ahead of difficult 1Q and 2020. Visibility on the resumption of normal business remains low, and despite full order books, no guidance was provided for 1Q or 2020. However management recognised that some significant contraction is to be expected in 1Q, especially from industrial activities in China (~20% of aroup sales), where business was conducted as usual for only two weeks in 1Q. Plants in the country are still not operating at full capacity, and the Wuhan plant is still closed. In Italy (19% of group sales), domestic sales have been blocked since last week and are likely to remain so until the end of the month, although plants in the country continue to fulfil orders from abroad. We estimate sales in 1Q are at risk of facing a ~20% headwind from restrictions in China, Italy.
- Change in estimates. We have lowered our '20E Industrial sales growth to a -3.1% fall (vs +6.5% growth previously), reflecting the slowdown of Industrial activities amid the tough situation in China and increasing restrictions and potentially declining demand in Europe. We have adopted a more cautious growth forecast for medical sales, lowered to +5.3% (from +9.7%). Overall we have reduced our '20E sales by -5% and our '20E EBIT by -20% to reflect the lost scale in Industrial activities and the slowdown in Medical growth. Our '20E EPS goes down by -11% as we have re-aligned our tax rate (26%) and minorities forecasts. We lower our FCF forecast by -72%, reflecting higher WC cash absorption and reduce our NFP forecast to €35mn (from €39mn, still not inclusive of temporary financial assets worth €15mn.
- OUTPERFORM confirmed, TP lowered to €26. We have lowered our DCF-based TP to €26 (from €34), reflecting our lower estimates and a higher WACC of 8% (ERP hiked by +50bps). A strong balance sheet, the resilient medical business, and positive exposure to strong longterm dynamics still power the equity story.

Key Figures	2018A	2019A	2020E	2021E	2022E
Sales (Eu mn)	346	401	409	454	495
Ebitda (Eu mn)	36	46	41	50	57
Net profit (Eu mn)	17	26	23	28	33
EPS - New Adj.(Eu)	0.870	1.333	1.181	1.451	1.672
EPS - Old Adj.(Eu)	0.870	1.166	1.323	1.560	
DPS (Eu)	0.400	0.400	0.400	0.400	0.400
Ratios & Multiples	2018A	2019A	2020E	2021E	2022E
P/E Adj.	18.4	12.0	13.5	11.0	9.6
Div. Yield	2.5%	2.5%	2.5%	2.5%	2.5%
EV/Ebitda Adj.	8.2	6.3	7.7	6.1	5.0
ROCE	21.7%	22.7%	16.4%	18.4%	20.9%

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein, and of any of its parts, is strictly prohibited. None of the contents of this document may be shared with third parties without Company authorization.



EL.EN. - 12m Performance



RATING: Unchanged

TARGET PRICE (Eu): from	n 34.00 to	26.00					
Ch. in Adj.EPS est:	2020E	2021E					
	-10.7%	-7.0%					
STOCK DATA							
Reuters code:		ELEN.MI					
Bloomberg code:		ELN IM					
Performance 1	m 3m	12m					
	% -50.5%						
Relative -7.2	% -15.2%	12.3%					
12 months H/L:	34	.58/16.00					
SHAREHOLDER DATA							
No. of Ord. shares (mr	No. of Ord. shares (mn):						
Total No. of shares (m	n):	20					
Mkt Cap Ord (Eu mn)	:	312					
Total Mkt Cap (Eu mn):	312					
Mkt Float - ord (Eu mn):	161					
Mkt Float (in %):		51.7%					
Main shareholder:							
Cangioli Andrea		15.2%					
BALANCE SHEET DATA		2020					
Book value (Eu mn):		235					
BVPS (Eu):		12.06					
P/BV:		1.3					
Net Financial Position	(Eu mn):	35					
Enterprise value (Eu m	nn):	319					

Please see important disclaimer on the last page of this report

Intermonte

N KEY FIGURES		2018A	2019A	2020E	2021E	202
	Fiscal year end	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/20
PROFIT & LOSS (Eu mn)	Sales	346	401	409	454	4
,	EBITDA	36	46	41	50	
	EBIT	30	38	33	41	
	Financial income (charges)	1	0	1	1	
	Associates & Others	(1)	(0)	0	0	
	Pre-tax profit (Loss)	30	39	33	42	
	Taxes	(8)	(10)	(9)	(11)	(
	Tax rate (%)	-26.1%	-25.5%	-26.0%	-26.0%	-26.
	Minorities & discontinue activities	(5)	(3)	(2)	(3)	
	Net profit	17	26	23	28	
	Total extraordinary items					
	Ebitda excl. extraordinary items	36	46	41	50	
	Ebit excl. extraordinary items	30	38	33	41	
	Net profit restated	17	26	23	28	
	Total shares out (mn) - average fd	19	20	20	20	
PER SHARE DATA (Eu)	EPS stated fd	0.870	1.333	1.181	1.451	1.0
	EPS restated fd	0.870	1.333	1.181	1.451	1.0
	BVPS fd	10.398	1.335	12.064	13.018	1.0
	Dividend per share (ord)	0.400	0.400	0.400	0.400	0.4
		0.400	0.400	0.400	0.400	0.4
	Dividend per share (sav) Dividend pay out ratio (%)	46.0%	30.0%	33.9%	27.6%	23
	Gross cash flow	27	37	33	40	20
CASH FLOW (Eu mn)			3/			
	Change in NWC	(17)	-	(18)	(12)	
	Capital expenditure	(26)	(23)	(10)	(8)	
	Other cash items	0	0	0	0	
	Free cash flow (FCF)	(16)	14	5	20	
	Acquisitions, divestments & others	3	(6)	(23)	0	
	Dividend	(8)	(9)	(9)	(8)	
	Equity financing/Buy-back	0	0	0	0	
	Change in Net Financial Position	(22)	(1)	(26)	12	
BALANCE SHEET (Eu mn)	Total fixed assets	68	89	90	89	
	Net working capital	80	80	98	110	
	Long term liabilities	9	11	32	29	
	Net capital employed	157	179	220	228	
	Net financial position	63	61	35	47	
	Group equity	219	241	255	275	:
	Minorities	19	19	20	21	
	Net equity	201	222	235	254	
[ERPRISE VALUE (Eu mn)	Average mkt cap - current	312	312	312	312	
	Adjustments (associate & minorities)	(42)	(42)	(42)	(42)	(
	Net financial position	63	61	35	47	,
	Enterprise value	292	293	319	307	
DATIOS(97)	EBITDA margin*	10.3%	11.6%	10.1%	11.1%	11
RATIOS(%)	EBIT margin*	8.7%	9.5%	8.0%	9.1%	9
	Gearing - Debt/equity	-28.5%	-25.5%	-13.8%	-17.2%	-22
	Interest cover on EBIT	-20.5%	-20.578 nm	-13.0% nm	nm	-22
	Debt/Ebitda					
		nm	nm	nm	nm	20
	ROCE*	21.7%	22.7%	16.4%	18.4%	20
		8.6%	12.3%	10.1%	11.6%	12
	EV/CE	2.1	1.7	1.6	1.4	
	EV/Sales	0.8	0.7	0.8	0.7	
	EV/Ebit	9.7	7.7	9.8	7.4	_
	Free Cash Flow Yield	-4.6%	4.0%	1.4%	5.7%	7
GROWTH RATES (%)	Sales	12.9%	15.8%	2.0%	11.1%	9
	EBITDA*	-1.4%	30.0%	-10.8%	21.5%	13
	EBIT*	-1.5%	27.4%	-14.4%	26.1%	16
	Net profit	7.4%	54.9%	-11.4%	22.9%	15

* Excluding extraordinary items

Source: Intermonte SIM estimates

4Q19/FY19 snapshot

El.En. 4Q19/FY19 results snapshot

(Eu mn)	4Q18A	4Q19A	4Q19E	AvE	2018A	2019A	2019E	ΑvΕ
Medical Segment	59.0	72.1	70.5	2%	197.9	242.2	241.3	0%
YoY growth %	17.1%	22.1%	19.5%		13.4%	22.4%	22.0%	
Industrial Segment	43.6	46.8	44.1	6%	148.2	158.6	156.3	1%
YoY growth %	15.7%	7.4%	1.3%		12.2%	7.0%	5.5%	
Sales	102.6	117.9	113.6	4%	346.0	400.8	396.6	1%
YoY growth %	16.5%	14.9%	10.7%		12.9%	15.8%	14.6%	
Gross profit	41.2	44.9	46.1	(3%)	137.5	156.0	157.2	(1%)
Gross margin %	40.1%	38.1%	40.6%		39.7%	38.9%	39.6%	
YoY growth %	8.0%	9.0%	11.9%		8.0%	13.5%	14.4%	
EBITDA	11.6	13.7	14.8	(7%)	35.6	46.3	47.4	(2%)
Ebitda margin %	11.3%	11.6%	13.0%		10.3%	11.6%	12.0%	
YoY growth %	20.9%	18.2%	27.7%		-1.4%	30.0%	33.1%	
ЕВП	10.0	11.8	11.9	(1%)	30.0	38.2	38.4	(0%)
Ebit margin %	9.7%	10.0%	10.5%		8.7%	9.5%	9.7%	
YoY growth %	20.4%	17.7%	19.5%		-1.5%	27.4%	28.0%	
Pretax Profit	9.6	11.0	11.3	(2%)	29.5	38.6	38.9	(1%)
Pretax margin %	9.4%	9.4%	9.9%		8.5%	9.6%	9.8%	
YoY growth %	18.8%	14.4%	16.8%		8.5%	30.8%	31.6%	
NetIncome					16.8	26.0	22.5	16%
NI Margin %					4.9%	6.5%	5.7%	
YoY growth %					7.4%	54.9%	34.0%	
OpCF					11.9	37.7	25.9	46%
Сарех					-26.3	-24.4	-22.0	
FCF (pre-M&A)					- 14.4	13.3	3.9	243%
Net financial position	62.5	61.4	30.4	1 02 %	62.5	61.4	30.4	

Source: Intermonte SIM and company data

Changes to estimates

Changes to estimates

	N	ew Estimat	es	С	ld Estimate	s		Delta %	
	2020	2021	2022	2020	2021	2022	2020	2021	2022
Revenue	409	454	495	430	479		-5%	-5%	
%YoY	2.0%	11.1%	9.0%	8.4%	11.4%				
EBITDA	41	50	57	51	58		-18%	-13%	
%YoY	-10.8%	21.5%	13.7%	6.7%	14.2%				
%margin	10.1%	11.1%	11.5%	11.8%	12.1%				
ЕВП	33	41	48	41	48		-20%	-14%	
%YoY	-14.4%	26.1%	16.6%	7.0%	16.7%				
%margin	8.0%	9.1%	9.7%	9.6%	10.0%				
EPS	1.18	1.45	1.67	1.32	1.56		-11%	-7%	
%YoY	-11.4%	22.9%	15.4%	13.4%	17.9%				
NFP	35	47	67	39	56		-11%	-15%	

Source: Intermonte SIM and company data



Changes to estimates

Top-line breakdown by segment

sreakdown	2017A	2018A	2019A	2020E	2021E	2022
Aesthetic	100.0	110.4	134.3	138.3	152.2	164.
growth YoY (%)	18.0%	10.4%	21.6%	3.0%	10.0%	8.0%
% of total sales	32.6%	31.9%	33.5%	33.9%	33.5%	33.29
Surgical	34.5	42.1	50.3	54.8	60.9	66.
growth YoY (%)	-9.0%	21.9%	19.5%	9.0%	11.0%	10.09
% of total sales	11.3%	12.2%	12.6%	13.4%	13.4%	13.59
Physiotherapy	9.4	10.8	10.6	11.1	12.0	12.
growth YoY (%)	8.5%	14.5%	8.5%	5.0%	8.0%	7.05
% of total sales	3.1%	3.1%	2.6%	2.7%	2.6%	2.65
Other medical lasers	0.2	0.7	1.1	0.3	0.3	0.
% of total sales	0.1%	0.2%	0.3%	0.1%	0.1%	0.19
Total Medical Systems	144.6	164.0	196.3	204.6	225.3	244.
growth YoY (%)	10.9%	13.4%	19.7%	4.2%	10.1%	8.4
% of total sales	47.2%	47.4%	49.0%	50.1%	49.6%	49.3
Medical service	29.9	33.9	45.9	50.5	55.5	60.
growth YoY (%)	-16.0%	13.5%	35.4%	10.0%	10.0%	9.0
% of total sales	9.7%	9.8%	11.5%	12.4%	12.2%	12.2
otal Medical Revenues	174.4	197.9	242.2	255.0	280.9	304
growth YoY (%)	5.0%	13.4%	22.4%	5.3%	10.1%	8.5
% of total sales	56.9%	57.2%	60.4%	62.4%	61.8%	61.6
Cutting	102.9	115.5	119.7	113.9	129.9	142
growth YoY (%)	66.8%	13.5%	3.6%	-4.8%	14.0%	10.0
% of total sales	33.6%	33.4%	29.9%	27.9%	28.6%	28.9
Marking	17.3	17.9	20.3	20.3	21.9	24
growth YoY (%)	27.7%	7.0%	13.4%	0.0%	8.0%	10.0
% of total sales	5.6%	5.2%	5.1%	5.0%	4.8%	4.9
Laser sources	3.4	4.9	4.4	4.5	4.8	5
growth YoY (%)	24.0%	10.0%	-10.2%	2.3%	7.0%	5.0
% of total sales	1.1%	1.4%	1.1%	1.1%	1.1%	1.0
Total Industrial Systems	123.7	138.6	144.7	139.0	156.9	172
growth YoY (%)	58.0%	12.0%	4.4%	-3.9%	12.9%	9.8
% of total sales	40.4%	40.0%	36.1%	34.0%	34.6%	34.8
Industrial service	8.3	9.6	13.9	14.6	16.3	18
growth YoY (%)	3.0%	5.0%	44.8%	5.0%	12.0%	10.0
% of total sales	2.7%	2.8%	3.5%	3.6%	3.6%	3.6
otal Industrial Revenues	132.0	148.2	158.6	153.6	173.2	190
growth YoY (%)	52.5%	12.2%	7.0%	-3.1%	12.8%	9.8
% of total sales	43.1%	42.8%	39.6%	37.6%	38.2%	38.4
otal Revenues	306.5	346.0	400.8	408.6	454.1	495

Source: Intermonte SIM and company data

Peer Group - Absolute Performances

Stock	Price	Ccy	Mkt cap	1M	3M	6M	YTD	1Y	2Y
EL.EN.	16.00	EUR	312	-46 .1%	-50.5%	-31.3%	-51.6%	-15.4%	-47.2%
AMADA CO.	799.00	JPY	283,754	-28.6%	-37.1%	-32.5%	-36.1%	-26.2%	-40.2%
BIOLASE	0.39	USD	12	-41.3%	-24.3%	-63.6%	-29.4%	-83.9%	-83.4%
CUTERA	13.87	USD	197	-48.6%	-62.4%	-53.1%	-61.3%	-24.2%	-74.6%
HAN'S LASER TECH IND.	30.18	CNY	31,741	-26.1%	-24.7%	-16.4%	-24.5%	-28.4%	-47.0%
NMODE	14.86	USD	487	-66.2%	-65.6%	-45.9%	-62.1%		
IPG PHOTONICS	124.25	USD	6,593	-10.9%	-16.5%	-12.4%	-14.3%	-19.1%	-49.7%
LUTRONIC	5290.00	HKD	137,158	-32.4%	-45.9%	-40.9%	-42.1%	-54.6%	-67.3%
PRIMA INDUSTRIE	10.78	EUR	112	-34.3%	-36.7%	-19.3%	-34.3%	-47.7%	-73.7%
RA MEDICAL	1.07	USD	15	-49.3%	39.0%	-37.1%	-5.3%	-75.8%	
SISRAM MEDICAL	2.71	HKD	1,198	-30.9%	-36.1%	-33.7%	-34.4%	-45.5%	-56.3%
Mean performance				-37.7%	-32.8%	-35.1%	-35. 9 %	-42 .1%	-59.9%
Italy FTSE Mib	15,314.8	EUR		-38.4%	-35.2%	-29.8%	-34.8%	-27.2%	-33.0%

Source: FactSet

Peer Group - Multiple Comparison

Stock	Price	Ссу	Mkt cap	EV/Sales	EV/Sales	EV/Ebitda	EV/Ebitda	EV/Ebit	EV/Ebit	P/E	P/E	Div Yield	Div Yield
		,	•	2020	2021	2020	2021	2020	2021	2020	2021	2020	2021
EL.EN.	16.00	EUR	312	0.8	0.7	7.7	6.1	9.8	7.4	13.5	11.0	2.5%	2.5%
AMADA CO.	799.00	JPY	283,754	0.7	0.6	3.9	3.5	5.8	4.9	10.3	9.1	6.1%	6.2%
BIOLASE	0.39	USD	12	0.3									
CUTERA	13.87	USD	197								132.1		
HAN'S LASER TECH IND.	30.18	CNY	31,741	2.5	2.1	16.9	14.6	20.4	16.3	20.8	17.3	0.6%	0.7%
INMODE	14.86	USD	487	0.8	0.2	1.9	0.6	2.0	0.6	8.1	6.9	0.0%	0.0%
IPG PHOTONICS	124.25	USD	6,593	4.3	3.6	16.1	11.2	23.9	14.9	37.1	25.1	0.0%	0.0%
LUTRONIC	5290.00	HKD	137,158										
PRIMA INDUSTRIE	10.78	EUR	112	0.5	0.5	5.9	4.8	17.5	10.5	17.3	9.7	2.6%	2.8%
RA MEDICAL	1.07	USD	15										
SISRAM MEDICAL	2.71	HKD	1,198										
Median				0.7	0.6	5.9	4.8	17.5	10.5	17.3	13.5	0.6%	0.7%

Source: Intermonte SIM estimates for covered companies, FactSet consensus estimates for peer group

EL.EN. - Estimates Comparison with Consensus

		2020			2021				
(Eu mn)	Intermonte	Consensus	%diff	Intermonte	Consensus	%diff			
Revenues	408.6	430.0	-5.0%	454.1	479.0	-5.2%			
Ebitda	41.3	51.0	-19.0%	50.2	58.0	-13.4%			
Net Profit	23.0	26.0	-11.4%	28.3	30.0	-5.6%			
EPS	1.181	1.323	-10.7%	1.451	1.560	-7.0%			
Net Debt	35.2	(39.0)	-190.2%	47.3	(56.0)	-184.4%			

Source: Intermonte SIM estimates and Factset consensus estimates

DETAILS ON STOCKS RECOMMENDATION

Stock NAME	EL.EN.		
Current Recomm:	OUTPERFORM	Previous Recomm:	OUTPERFORM
Current Target (Eu):	26.00	Previous Target (Eu):	34.00
Current Price (Eu):	16.00	Previous Price (Eu):	26.06
Date of report:	18/03/2020	Date of last report:	28/02/2020



DISCLAIMER (for more details go to DISCLAIMER)

IMPORTANT DISCLOSURES

nmendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties with The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte. This report is directed exclusively at market professional and other institutional investors (Institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any

investment or service to which this report may relate will not be made available to Non-Institution.

The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a solicitation to buy or

set securities. This disclaimer is constantly updated on Intermonte's website <u>www.intermonte.it</u> under LEGAL INFORMATION. Valuations and recommendations can be found in the text of the most recent research and/or reports on the companies in question. For a list of all recommendations made by Intermonte on any financial instrument or issuer in the last twelve months consult the <u>PERFORMANCE</u> web page. Intermonte distributes research and engages in other approved activities with respect to Major U.S. Institutional Investors ("Majors") and other Qualified Institutional Buyers ("QIBs"), in the United States, via Brasil Plural Securities LLC under SEC 15a-6 guidelines. Intermonte is not registered as a broker dealer in the United States under the Securities Exchange Act of 1394, as amended (the "Exchange Act"), and is not a member of the Securities Investor Protection Corporation ("SIPC"). Brasil Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC.

ANALYST CERTIFICATION

For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securities. The analyst (s) also certify that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report. The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including Intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although

this is minimal in comparison to that generated by brokerage activities. Intermonte's internal procedures and codes of conduct are aimed to ensure the impartiality of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the

schange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are made. The analyst responsible for the report is <u>not</u> a) a resident of US; b) an associated person of a U.S. broker-dealer; c) supervised by a supervisory principal of a U.S. broker-dealer. This Research Report is distributed in the U.S. through Brasil Plural Securities LLC, 545 Madison Avenue, New York 10022.

GUIDE TO FUNDAMENTAL RESEARCH

Source for environment new Reservice. The main methods used to evaluate financial instruments and set a target price for 12 months after the investment recommendation are as follows: • Discounted cash flow (DCF) model or similar methods such as a dividend discount model (DDM)

- Comparison with market peers, using the most appropriate methods for the individual company analysed: among the main ratios used for industrial sectors are price/ earnings (P/E), EV/EBITDA, EV/EBIT, price /sales
- Return on capital and multiples of adjusted net book value are the main methods used for banking sector stocks, while for insurance sector stocks return on allocated capital and multiples on net book value and embedded portfolio value

are used • For the utilities sector comparisons are made between expected returns and the return on the regulatory asset base (RAB) Some of the parameters used in evaluations, such as the risk-free rate of 2.5% and a risk premium, are the same for all companies covered, and are updated to reflect market conditions. Currently a risk-free rate of 2.5% and a risk premium of 5.0% are being used.

Frequency of research: quarterly

Reports on all companies listed on the S&PMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published.

A draft copy of each report may be sent to the subject company for its information (without target price and/or recom Explanation of our ratings system: BUY: stock expected to outperform the market by over 25% over a 12 month period; OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period; NEUTRAL: stock performance expected at between +10% and -10% compared to the market over a 12 month period; UNDERPERFORM: stock expected to underperform the market by between -10% and -25% over a 12 month period; CUI under the superiod and expected at between 50% used 14 meret between 20% over a 12 month period; SELL: stock expected to underperform the market by over 25% over a 12 month period. Prices: The prices reported in the research refer to the price at the close of the previous day of trading

CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms. As at 31 December 2019 Intermonte's Research Department covered 121 companies. Intermonte's distribution of stock ratings is as follows:

BUY:	10,94 %
OUTPERFORM:	50,00 %
NEUTRAL:	35,15 %
UNDERPERFORM	03,91 %
SELL:	00,00 %

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (48 in total) is as follows:

BUY:	12,50 %	
OUTPERFORM:	60,42 %	
NEUTRAL:	27,08 %	
UNDERPERFORM	00,00 %	
SELL:	00,00 %	

CONFLICT OF INTEREST

In order to disclose its possible conflicts of interest Intermonte SIM states that:

within the last year, Intermonte SIM managed or co-managed/is managing or is co-managing an Institutional Offering and/or managed or co-managed/is managing or is co-managing an offering with firm commitment underwriting of the securities of the following Companies: Capital For Progress 2, IEG, Techedge

Intermonte SIM is acting as placement agent in II Sole 24 Ore's capital increase with an agreement with the company for the publication of an equity research regarding the company and the transaction. Intermonte will receive fees from the company for its activity as placement agent.

Intermonte SIM has provided in the last 12 months / provides / may provide investment banking services to the following companies: Aedes, Aeroporto di Bologna, Alkemy, Banca Ifis, Cellularline, ePrice, Falck Renewables, Gamenet, H-Farm, Iervolino, Mittel, Retelit, Saes Getters, Saras, Wiit.

Intermonte SIM is Specialist and/or Corporate Broker and/or Sponsor and/or Broker in charge of the share buy back activity of the following Companies: Abitare In. Aedes, Alkemy, Aguafil, ASTM, Avio, Azimut, B&C Speakers, Banca Ifis, Banca Sistema, B., Brioschi Svillopol Immobiliare, Cattolica Assicurazioni, CFT, Cellularline, DeA Capital, JogiTouch, ELEn, Eles, Elica, Emak, ePrice, Falck Renevables, Fine Foods, Finit Fondo Alpha, First Capital, Gamenet, Gerfan, GO Internet, GPI, Guala Closure, H-Farm, Iervolino Entertainment, IEG, Indel B, Industrial Star of Italy 3, Italiaonline, LU-VE, Notorious Picture, Nova RE, Openjobmetis, QF Alpha Immobiliare, Reno de Medici, Reply, Retelit, Saes Getters, Servizi Italia, Sesa, Somec, Tamburi Investment Partners, Tesmec, Tinexta, TXT e-solutions, Vetrya, Wiit.

Intermonte SIM has a contractual commitment to act as liquidity provider on behalf of third parties for the following companies: Banca Sistema, Cattolica, Restart.

Intermonte SIM performes as a market maker for the following companies: A2A, Anima, Atlantia, Autogrill, Azimut Holding, BAMI, Banca Generali, Banca Mediolanum, Brembo, Buzzi, CNHI, Enel, ENI, Exor, Fineco. FCA, FTMIB, Generali, Italgas, Iren, Intesa Sanpaolo, Leonardo, Mediobanca, Moncler, Mediaset, Pirelli&C, Prysmian, Poste, Ferrari, Saipem, Snam, STM, Tenaris, Telecom Italia, Sav, Terna, UBI, Unicredit, Unipol, UnipolSai.

Intermonte SIM is a member of the CBOE Europe Equities Liquidity Provider Program for the following financial instruments: A2A, Atlantia, ATSM, Autogrill, Azimut Holding, Banca Generali, Banca Mediolanum, Banco BPM, Bca Monte dei Paschi di Siena, Bca Pop Emilia Romagna, Banca Pop Sondrio, Buzzi Unicem, Buzzi Unicem rsp. Campari, CIR- Compagnie Industriali Riunite, Credito Emiliano, Danieli & C., Porte Italiano, Danzei Unicem, Buzzi Unicem, Buzzi Unicem, Senterali, Hera, Intesa Sanpaolo, Iren, Italgas, Italmobiliare, Leonardo, Maire Tecnimont, Mediaset, Mediobanca, Pirelli & C., Porte Italiano, Porsman, Recordati, SIAS., Saipem, Salini Impregilo, Salvatore Ferragamo, Snam, Telecom Italia, Telecom Italia rsp. Terna, Tod's, UBI Banca, Unicredit, Unipol, Unipolsai.

Through its Websim Division, Intermonte SIM acts as an Retail Investor Research Provider on behalf in regard to the following companies: Aedes, Banca Ifis, Banca Sistema, Cattolica Assicurazioni, Cellularline, CFT Group, Circle, Coima RES, Comer Industries, Crowdfundme, Digital Bros, Digital Magics, Elettra Investimenti, Falck Renewables, Fiera Milano, Finlogic, First Capital, FOPE, Gefran, Generali Assicurazioni, Giglio, Go Internet, H-Farm, Ilpra, Indel B, ISI/Salcef, Italiaonline, La Doria, LVenture, MailUp, Maps, Masi Agricola, Molmed, Neodecortech, Piaggio, Portale Sardegna, Primi sui Motori, Retelit, Safe Bag, Somec, SOS Travel, Tinexta, TPS, WITT,

Through its Websim Division, Intermonte SIM carries out marketing / communication activities on behalf of the following equity crowdfunding 200Crowd, BacktoWork24, Crowdfundme, Opstart and the following issuers: Banca IMI, BNP Paribas, Credit Suisse, Exane, Leonteg, Unicredit, Vontobel, Wisdomtre

Intermonte SIM SpA holds net long or short positions in excess of 0.5% of the overall share capital in the following issuers

Emittente	%	Long/Short
GABELLI VALUE FOR ITALY AZ. ORD	0,54	LONG
LIFE CARE CAPITAL	0,52	LONG
SPACTIV	1,08	LONG
THESPAC	0,73	LONG
VET 1	0.62	LONG

© Copyright 2020 by Intermonte SIM - All rights reserved

© Copyright 2020 by Intermonte SIM - All rights reserved It is a violation of national and intermational copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM you are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM. INTERMONTE Will take legal action against any hody dramsmitting/publishing its Research products without its express authorization. INTERMONTE Sim strongly believes its research product on Italian equities is a value added product and deserves to be adequately paid.

Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONTE research product

INTERMONTE SIM is MIFID compliant - for our Best Execution Policy please check our Website MIFID Further information is available